Guangzhou-Israel Biotechnology Fund (GIBF)
About
Our unique Guangzhou-Israel Biotechnology Fund (GIBF) creates added value for Israeli, European and American companies looking to expand in China. With years of life sciences expertise, private equity investment experience, local knowledge based on over a decade of activity in China, and numerous foreign companies already established in China, GIBF serves as an invaluable strategic investor and partner in China with a proven ability and track record of conducting multi-center clinical trials in top-tier Chinese hospitals, providing the resources and networks for securing successful NMPA submissions, commercializing products and developing manufacturing capacity to satisfy both local and global demand.
Key facts
- Website
- gibf-bio.com
- Type
- Venture Capital
- Headquarters
- Israel
- Portfolio companies
- 1
- Stages
- Series C
- Cheque size
- $10M to $10M
- Sector focus
- Life SciencesImmunotherapyImmunologyCancerCancer Immunotherapy
Recent investments
| Date | Company | Round | Amount |
|---|---|---|---|
| 6 May 2024 | Nectin Therapeutics | Series C | $10M |
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
What companies has Guangzhou-Israel Biotechnology Fund (GIBF) invested in?
Guangzhou-Israel Biotechnology Fund (GIBF) has invested in Nectin Therapeutics.
SEC filings, insider activity, nonprofit links and pay benchmarks for Guangzhou-Israel Biotechnology Fund (GIBF):

